ClinicalCodes.org

An online clinical codes repository to improve validity and reproducibility of medical database research

Research article:

Withdrawing Performance Indicators: Retrospective Analysis of General Practice Performance Under the UKs Quality and Outcomes Framework

Reference:

Kontopantelis, Evangelos; Springate, David; Reeves, David; Ashcroft, Darren; Valderas, Jose M; Doran, Tim(2014) Withdrawing Performance Indicators: Retrospective Analysis of General Practice Performance Under the UKs Quality and Outcomes Framework. British Medical Journal, doi: http://dx.doi.org/10.1136/bmj.g330

Link to fulltext article
Abstract
Objectives: To investigate the effect of withdrawing incentives on recorded quality of care, in the context of the UK Quality and Outcomes Framework pay-for-performance scheme. Design: Retrospective longitudinal study. Setting: Data for 644 general practices, from 2004/5 to 2011/12, extracted from the Clinical Practice Research Datalink. Participants: All patients registered with any of the practices over the study period, 13,772,992 in total. Intervention: The removal of financial incentives for aspects of care for patients with asthma, coronary heart disease, diabetes, stroke and psychosis. Main outcome measures: Performance on eight clinical quality indicators withdrawn from a national incentive scheme: influenza immunisation (asthma) and lithium therapy monitoring (psychosis), removed in April 2006; blood pressure monitoring (coronary heart disease, diabetes, stroke), cholesterol level monitoring (coronary heart disease, diabetes) and blood glucose monitoring (diabetes), removed in April 2011. Multilevel mixed effects multiple linear regression models were used to quantify the effect of incentive withdrawal. Results: Mean levels of performance were generally stable after the removal of the incentives, both short- and long-term. For the two indicators removed in April 2006/7, levels in 2011/12 were very close to 2005/6 levels, although a small but statistically significant drop was estimated for influenza immunisation. For five of the six indicators withdrawn in from April 2011/12, there was no significant impact on performance in that year following removal and differences between predicted and observed scores were small. Performance on related outcome indicators retained in the scheme (e.g. blood pressure control) was generally unaffected. Conclusions: Following the removal of incentives, levels of performance across a range of clinical activities generally remained stable. This indicates that health benefits from incentive schemes can potentially be increased by periodically replacing existing indicators with new indicators relating to alternative aspects of care. However, most of the aspects of care we investigated remained indirectly incentivised and further work is required to assess the generalisability of the findings when incentives are fully withdrawn.
Author for correspondence
Evangelos Kontopantelis
Email for correspondence
e.kontopantelis@manchester.ac.uk

Code list: Lithium_drugcodes

23 codes in list

Code Coding system Description Entity type List name BNF_header BNF_code drug_substance_name
10292 CPRD_product_code LITHIUM 250 MG CAP drug Lithium_drugcodes Unknown 0
10809 CPRD_product_code PRIADEL liquid 520mg/5ml [SANOFI/AVE] drug Lithium_drugcodes Antimanic drugs 4020300 lithium citrate
10937 CPRD_product_code lithium citrate oral liquid 509mg/5ml drug Lithium_drugcodes Antimanic drugs 4020300 lithium citrate
11491 CPRD_product_code lithium citrate sugar free liquid 520mg/5ml drug Lithium_drugcodes Antimanic drugs 4020300 lithium citrate
12402 CPRD_product_code CAMCOLIT 250 tablets [NORGINE] drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
12403 CPRD_product_code CAMCOLIT 400 tablets [NORGINE] drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
12648 CPRD_product_code lithium citrate oral liquid 1.018g/5ml drug Lithium_drugcodes Antimanic drugs 4020300 lithium citrate
13601 CPRD_product_code lithium citrate modified release tablet 564mg drug Lithium_drugcodes Antimanic drugs 4020300 lithium citrate
13654 CPRD_product_code LITAREX CR tablets 564mg [ACTAVIS] drug Lithium_drugcodes Antimanic drugs 4020300 lithium citrate
1447 CPRD_product_code lithium carbonate modified release tablet 400mg drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
14954 CPRD_product_code lithium carbonate modified release tablet 450mg drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
15388 CPRD_product_code PHASAL tablets 300mg [LAGAP] drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
15660 CPRD_product_code LITHIUM 10.8 MMOLS/5MLS LIQ drug Lithium_drugcodes Unknown 0
16250 CPRD_product_code LITHONATE sustained release tablets 400mg [APS] drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
22018 CPRD_product_code LI-LIQUID solution 509mg/5ml [ROSEMONT] drug Lithium_drugcodes Antimanic drugs 4020300 lithium citrate
25344 CPRD_product_code LITHIUM CARBONATE modified release tablet 400mg [APS] drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
25345 CPRD_product_code LI-LIQUID solution 1.018g/5ml [ROSEMONT] drug Lithium_drugcodes Antimanic drugs 4020300 lithium citrate
3352 CPRD_product_code LISKONUM tablets 450mg [GLAXSK PHA] drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
3359 CPRD_product_code PRIADEL tablets 200mg [SANOFI/AVE] drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
760 CPRD_product_code lithium carbonate modified release tablet 200mg drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
8041 CPRD_product_code lithium carbonate tablets 250mg drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
872 CPRD_product_code PRIADEL tablets 400mg [SANOFI/AVE] drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate
8827 CPRD_product_code lithium carbonate modified release tablet 300mg drug Lithium_drugcodes Antimanic drugs 4020300 lithium carbonate

0 comments have been posted.

Please log in to leave a comment.